{"url_path":"/sec/anip/8-k/2026-02-27/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-02-27","source_url":"https://www.sec.gov/Archives/edgar/data/1023024/0001023024-26-000013-index.html","accession_number":"0001023024-26-000013","cik":"0001023024","ticker":"ANIP","issuer_name":"ANI PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1023024/0001023024-26-000013-index.html","primary_entity_key":"0001023024","primary_entity_name":"ANI PHARMACEUTICALS INC"},"word_count":47,"has_tables":true,"body_markdown":"Item 2.02Results of Operations and Financial Condition\n\nOn February 27, 2026, ANI Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.*"}